secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2025-08-22T23:59:59+00:00
Accession:  0001171843-25-005555
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose appoints EY as auditor, receives $1.5M advance from Hanmi for AML drug
-----------------------------------------------------------------------------

- Shareholders voted to appoint Ernst & Young as independent auditor at reconvened annual meeting.
- Received additional $1.5M advance from Hanmi under $8.5M loan facility, total drawn now $7.1M.
- Funds support continued clinical development of tuspetinib-based triplet therapy for AML.
- Aptose is a clinical-stage oncology company focused on front-line AML treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184325005555/0001171843-25-005555-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184325005555/f8k_082225.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-005555

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer